Literature DB >> 20340137

Allelic imbalance of expression and epigenetic regulation within the alpha-synuclein wild-type and p.Ala53Thr alleles in Parkinson disease.

Gerassimos E Voutsinas1, Eleana F Stavrou, Gerassimos Karousos, Aggeliki Dasoula, Adamantia Papachatzopoulou, Maria Syrrou, Annemieke J M H Verkerk, Peter van der Spek, George P Patrinos, Reinhard Stöger, Aglaia Athanassiadou.   

Abstract

Genetic alterations in the alpha-synuclein (SNCA) gene have been implicated in Parkinson Disease (PD), including point mutations, gene multiplications, and sequence variations within the promoter. Such alterations may be involved in pathology through structural changes or overexpression of the protein leading to protein aggregation, as well as through impaired gene expression. It is, therefore, of importance to specify the parameters that regulate SNCA expression in its normal and mutated state. We studied the expression of SNCA alleles in a lymphoblastoid cell line and in the blood cells of a patient heterozygous for p.Ala53Thr, the first mutation to be implicated in PD pathogenesis. Here, we provide evidence that: (1) SNCA shows monoallelic expression in this patient, (2) epigenetic silencing of the mutated allele involves histone modifications but not DNA methylation, and (3) steady-state mRNA levels deriving from the normal SNCA allele in this patient exceed those of the two normal SNCA alleles combined, in matching, control individuals. An imbalanced SNCA expression in this patient is thus documented, with silencing of the p.Ala53Thr allele and upregulation of the wild-type-allele. This phenomenon is demonstrated for a first time in the SNCA gene, and may have important implications for PD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20340137     DOI: 10.1002/humu.21248

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  21 in total

Review 1.  Epigenetic regulation in Parkinson's disease.

Authors:  Catherine Labbé; Oswaldo Lorenzo-Betancor; Owen A Ross
Journal:  Acta Neuropathol       Date:  2016-06-29       Impact factor: 17.088

2.  Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease.

Authors:  Almas Siddiqui; Shankar J Chinta; Jyothi K Mallajosyula; Subramanian Rajagopolan; Ingrid Hanson; Anand Rane; Simon Melov; Julie K Andersen
Journal:  Free Radic Biol Med       Date:  2012-06-15       Impact factor: 7.376

Review 3.  Genetic variability in SNCA and Parkinson's disease.

Authors:  Lasse Pihlstrøm; Mathias Toft
Journal:  Neurogenetics       Date:  2011-07-29       Impact factor: 2.660

Review 4.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

Review 5.  α-Synuclein in Parkinson's disease.

Authors:  Leonidas Stefanis
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

Review 6.  Histone Modifications in Neurological Disorders.

Authors:  Bradley J Smith; Victor Corasolla Carregari
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 7.  Epigenetic landscape of Parkinson's disease: emerging role in disease mechanisms and therapeutic modalities.

Authors:  Navneet Ammal Kaidery; Shaista Tarannum; Bobby Thomas
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

8.  The Ala53Thr Mutation in the α-Synuclein Gene in an Indian Patient with Young-Onset Parkinson's Disease.

Authors:  Sanjay Pandey; Laxmikant Ramkumarsingh Tomar
Journal:  Mov Disord Clin Pract       Date:  2021-04-04

9.  Genetics and epigenetics of Parkinson's disease.

Authors:  Fabio Coppedè
Journal:  ScientificWorldJournal       Date:  2012-05-01

10.  Blood transcriptomics of drug-naïve sporadic Parkinson's disease patients.

Authors:  Raffaella Calligaris; Mihaela Banica; Paola Roncaglia; Elisa Robotti; Sara Finaurini; Christina Vlachouli; Lucia Antonutti; Francesco Iorio; Annamaria Carissimo; Tatiana Cattaruzza; Andrea Ceiner; Dejan Lazarevic; Alberto Cucca; Nicola Pangher; Emilio Marengo; Diego di Bernardo; Gilberto Pizzolato; Stefano Gustincich
Journal:  BMC Genomics       Date:  2015-10-28       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.